Stockreport

Mesoblast R&D Day: Ryonsel Gains Traction, Back Pain Phase III Nears Finish, New Shots on Goal [Yahoo! Finance]

Mesoblast Limited - American Depositary Shares  (MESO) 
US:NASDAQ Investor Relations: investorsmedia.mesoblast.com
PDF approval at 30, 98% U.S. lives covered with no denied on-label claims, and an initial real-world 84% survival in severe pediatric GVHD, with management targeting a path [Read more]